Phase II/III randomized clinical trial of individualized adaptive radiotherapy guided by radiosensitivity (RAPART) in locally advanced non-small cell lung cancer patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500095615

Enrollment

Unknown

Registered

2025-01-09

Start date

2025-03-01

Completion date

Unknown

Last updated

2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

Experimental group:Individualized Adaptive Radiotherapy (RAPART)

Standard group:Standard radiotherapy

Eligibility

Sex/Gender

All

Age

19 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Adult patients, aged over 18 years old; 2) Non small cell lung cancer that requires pathological confirmation; 3) Must be considered surgically unresectable or medically inoperable; 4) ECOG physical condition is 0-2; 5) Patients who have undergone chemotherapy, targeted therapy, or immunotherapy before enrollment, as well as those who have contraindications to chemotherapy or are firmly unwilling to undergo chemotherapy, immunotherapy, or targeted therapy, are also eligible for enrollment.

Exclusion criteria

Exclusion criteria: 1) Prisoners who are not convenient for close clinical follow-up; 2) Patients with contraindications to radiotherapy.

Design outcomes

Primary

Measure	Time frame
Overall survival (OS);	—

Secondary

Measure	Time frame
Progression free survival (PFS);Localized progression free survival (LPFS);	—

Countries

China

Contacts

Public ContactFeng Ming (Spring) Kong

University of Hong Kong Shenzhen Hospital

kong0001@hku.hk+86 188 0755 0703

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026